舌下减敏疗法治疗花粉全身性成效高

费城（路透社健康专栏）12月21日电—据《变态反应，哮喘及病毒学年鉴》月刊11月刊一篇媒体报道，舌下减敏疗法（SLIT）病人球根归因于的呼吸道过敏成效高。“来顺利完成SLIT减少鼻炎的并发症及抑制剂购物，降低社会制度经济支出，”威尼斯Genoa大学Giovanni Passalacqua芝加哥大学真是。“之前之前有加速施打疗法降低社会制度支出，但这是首次对实用疗法（SLIT）顺利完成严格风险评估的结果。”Passalacqua芝加哥大学及其同事们对球根归因于的过敏功能性鼻炎和哮喘治果顺利完成研究，风险评估来顺利完成SLIT结合国际标准病人及基本上来顺利完成国际标准病人的费用及。研究人员媒体报道，SLIT使63.1%的病征病征更佳，并持续功能性51.8%的病征用到哮喘，而基本上控制系统设计国际标准疗法仅仅使23.2%的病征病征更佳，持续功能性28.9%的病征用到哮喘。而且同国际标准病人相比，SLIT的直接及间接费时均减低：SLIT病征病人的总体费时很低国家卫生保健控制系统预见的4周内基本上抑制剂病人费时，并且很低社会制度公众预见的2周内基本上抑制剂病人费时。“SLIT并不能算是加速施打疗法的的公司，” Passalacqua芝加哥大学暗示真是，“而是将其作为病人方法的另一选择。它最大的优点在于其最优的安全功能性和病征的尚可接受功能性。”“SLIT在英国未有正式控制系统设计，尽管一些变态反应专家控制系统设计它（并且取得了满意的结果），” Passalacqua芝加哥大学真是。“欧洲情况实质上不同，SLIT在很多国家中的飞速发展（如威尼斯，瑞典，荷兰，西班牙，智利，希腊及捷克）。”意味着的缺陷是SLIT未有得到FDA的批准，“Passalacqua芝加哥大学补足道。“受到FDA支持的临床研究正在顺利完成中的，并有望得到批准。” Sublingual Immunotherapy Cost-Effective for Pollen-Induced AllergyBy Will Boggs, MDNEW YORK (Reuters Health) Dec 21 - Sublingual immunotherapy (SLIT) is cost-effective for treating s with pollen-induced respiratory allergy, according to a report in the November Annals of Allergy, Asthma Andrew Immunology."The use of SLIT leads to a socio-economic sings by reducing the comorbidities of rhinitis and drug consumption," Dr. Giovanni Passalacqua from University of Genoa, Italy told Reuters Health. "This fact has been previously envisaged also for injection IT, but this is the first rigorous assessment made by means of a validated economic model."Dr. Passalacqua and colleagues' study was designed to evaluate the costs and consequences of using SLIT in association with standard treatment compared with standard treatment alone in young s with pollen-induced allergic rhinitis and asthma.SLIT improved symptoms of 63.1% of patients and prevented asthma in 51.8% of patients, the authors report, compared with 23.2% and 28.9%, respectively, of patients receiving standard treatment.Compared with standard treatment, SLIT resulted in lower direct and indirect expenses, the researchers note.According to the results, the overall cost of treatment for SLIT patients drops below that for patients receiving only drugs at year 4 from the National Healthcare System perspective and at year 2 from the societal perspective."SLIT is not to be intended as an antagonist of injection IT," Dr. Passalacqua explained, "rather as an additional therapeutic option. Its best advantage is the optimal safety profile and the good acceptance by the patients.""SLIT is not officially in use in the USA, although some allergists utilize it (with satisfactory results)," Dr. Passalacqua said. "In Europe the situation is completely different, and SLIT is widely used in many countries (e.g., Italy, Germany, France, Spain, Portugal, Greece, and Hungary).""The problem is formal, due to the fact that SLIT has not the approval of the FDA," Dr. Passalacqua added. "Clinical studies endorsed by the FDA are currently ongoing to get the approval."Ann Allergy Asthma Immunol 2006;97:615-621.

出版人：蓝色梦幻